



- **529** Hepatitis B Outbreak in a State Correctional Facility, 2000
- 532 Influenza and Pneumococcal Vaccination Levels Among Persons Aged ≥65 Years — United States, 1999
- 538 Routinely Recommended HIV Testing at an Urban, Urgent-Care Clinic — Atlanta, Georgia, 2000

Hepatitis B Outbreak in a State Correctional Facility, 2000

On March 31, 2000, acute hepatitis B was confirmed serologically in a 34-year-old man (index patient) who had been incarcerated for 2.5 years at a high-security state correctional facility and who presented to the facility medical unit with jaundice and abnormal liver enzymes. He reported having unprotected sex with his cellmate as his only risk factor for infection during the 6 months preceding his illness. Serologic testing of the 21-year-old cellmate confirmed that he had chronic hepatitis B virus (HBV) infection. He reported no history of symptoms compatible with hepatitis and was previously unaware of his chronic infection, but he did report having unprotected sex with the index patient and two additional inmates in the dormitory (dorm Y). On May 15, 2000, the state's department of health and department of corrections and CDC initiated an investigation to identify additional cases and determine risk factors for HBV infection. This report summarizes the results of the investigation, which identified additional cases of HBV infection in this correctional facility and underscores the need to implement hepatitis B vaccination in correctional facilities.

Current inmates who had resided in dorm Y at any time since October 1, 1999, were offered serologic testing for HBV infection and were interviewed about exposures during the preceding 6 months, including sexual activity, being tattooed, sustaining a cut or injury, being exposed to another inmate's blood, sharing a razor, and injection drug use. Acute HBV infection was defined as the presence of IgM antibody to hepatitis B core antigen (IgM anti-HBc) with or without the presence of hepatitis B surface antigen (HBsAg). Chronic HBV infection was defined as the presence of HBsAg and total (IgG and IgM) anti-HBc, and absence of IgM anti-HBc. Resolved infection was defined as the presence of total anti-HBc, but absence of IgM anti-HBc and HBsAg. Persons testing negative for anti-HBc and HBsAg were considered susceptible to HBV infection.

Of 103 eligible inmates, 97 (94%), including the sexual contacts of the inmate with chronic infection, consented to serologic testing. Of these 97 inmates, six (6%) had acute HBV infection, one (1%) had chronic infection, and 16 (16%) had resolved infection. The acute HBV infection rate among susceptible dorm Y inmates was 8%. Two inmates reported nonspecific symptoms (e.g., influenza-like illness) during the preceding 6 months. In addition to the index patient, one of the two other sexual contacts of the inmate with chronic infection.

The six inmates with acute infection and 70 (95%) of 74 susceptible inmates were interviewed. Having sex with another man was the only risk factor associated with acute HBV infection (risk ratio=12.2; 95% confidence interval=3.5–42.2) and accounted for two of six acute infections (Table 1).

Hepatitis B Outbreak — Continued

	No.	Infe	cted	No.	Infe	cted		
Exposure	exposed	No.	(%)	unexposed	No.	(%)	RR⁺	95% Cl [§]
Sex with a man	3	2	(66.7)	73	4	(5.5)	12.2	(3.5–42.2)
Cut or injured	33	4	(12.1)	43	2	(4.7)	2.6	(0.5–13.3)
Exposed to blood	8	1	(12.5)	68	5	(7.4)	1.7	(0.2–12.8)
Tattooed	11	0	_	65	6	(9.2)	0.0	(0.0- 2.3)
Shared a razor	4	0		72	6	(8.3)	0.0	(0.0- 5.6)

TABLE 1. Number of inmates infected with acute hepatitis B virus who resided in a dormitory at a state correctional facility, by type of exposure, May 2000*

* n=76.

[†] Relative risk.

[§] Confidence interval.

The correctional facility is comprised of 14 dormitories housing 96 inmates each; it operates at 99% capacity. Inmates move within the facility to participate in daily scheduled activities and frequently move among dormitories during their incarceration. Condoms are not available to inmates. Because of the HBV transmission in dorm Y, on June 6, 2000, serologic testing was offered to inmates who resided in the remainder of the facility to determine if further HBV transmission had occurred.

Of 1247 inmates in the remainder of the facility, 1026 (82%) consented to serologic testing and completed a self-administered questionnaire, which collected information on demographic characteristics and history of behaviors or characteristics that may have placed them at risk for HBV infection both during incarceration and during their lifetime. Of the 1026 inmates, 10 (1%) had chronic HBV infection and 178 (17%) had resolved infection. Of 838 susceptible inmates, five (<1%) were identified with previously undiagnosed acute HBV infection, resulting in an acute infection rate of 0.6% among inmates who did not reside in dorm Y, and an overall infection rate of 1.2% (11 of 918). Of the inmates with acute infection who did not reside in dorm Y, two were housed in one dormitory and the remainder resided in three other dormitories. None reported risk factors for HBV infection during the preceding 6 months.

Risk behaviors were evaluated to determine the potential for susceptible inmates to acquire HBV infection. Among the 907 susceptible inmates who completed the questionnaire, 473 (52%) reported at least one exposure while incarcerated that could have resulted in HBV transmission. These included injecting drugs (21 [2%] of 902), having sex with another man (36 [4%] of 899), using a razor that had been used by another inmate (73 [8%] of 900), and receiving a tattoo (429 [48%] of 898). Lifetime histories of risk factors associated with HBV infection also were reported frequently by susceptible inmates and included having received treatment for a sexually transmitted disease (STD) (328 [37%] of 896), having had >50 female sexual partners (110 [13%] of 838), having injected drugs (78 [9%] of 899), and having had sex with men (26 [3%] of 900).

To control the outbreak, the state's department of corrections offered hepatitis B vaccination to all susceptible inmates in dorm Y. In addition, acutely and chronically infected inmates were notified of their infection status, received a clinical assessment, and postexposure prophylaxis was provided to their contacts. The state's department of health and department of corrections are collaborating to implement routine hepatitis B vaccination for all inmates in the correctional system.

Reported by: State Dept of Health; State Dept of Corrections. Epidemiology Program Office; Div of Viral Hepatitis, National Center for Infectious Diseases; Div of STD Prevention, National Center for HIV, STD, and TB Prevention; and an EIS Officer, CDC.

Hepatitis B Outbreak — Continued

Editorial Note: The findings in this report document HBV transmission in a correctional facility, including a cluster of cases of acute infection in one dormitory and additional cases distributed throughout the facility. Most persons with acute HBV infection in the correctional facility were asymptomatic, and serologic surveys were needed to determine the extent of HBV transmission. The overall infection rate of 1% reflected infections acquired during the preceding 6 months and was higher than the estimated incidence of 1% per year in previous studies (*1,2*). This serologic survey also indicated that 1% of inmates had chronic infection and that none were aware of their infection status.

HBV is transmitted primarily by percutaneous or permucosal exposures to an infected person. Risk factors associated with HBV infection include having multiple sex partners, having had an STD, being a man who has sex with men, injection drug use, and being a sexual or nonsexual household contact of a person with chronic HBV infection (*3*). Receiving a tattoo has not been associated with community acquired HBV infections among nonincarcerated populations in the United States (*4*); however, transmission could occur if the tattoo is applied using contaminated equipment.

Sex with another man accounted for only 20% of new infections in this investigation. However, this and other behaviors prohibited by the correctional facility (e.g., injecting drugs) probably are underreported by inmates. Inmates with previously unrecognized chronic HBV infection may have served as a source for infection, similar to household contacts of persons with chronic infection (5). Housing data were not available to determine if persons with acute HBV infection were more likely to have been a cellmate of a chronically infected inmate.

The findings in this report are consistent with previous reports of HBV transmission in prison settings (1,2). Since 1982, the Advisory Committee on Immunization Practices has recommended hepatitis B vaccination of long-term inmates with a history of risk factors for infection (3). Although a large proportion of inmates in this prison reported current or previous risk factors for HBV infection, none of the susceptible inmates had been vaccinated.

In the state correctional system in this report, approximately one third of inmates are released each year (Department of Corrections, unpublished data, 2000). Previously incarcerated persons represent a population at risk for HBV infection. Approximately 30% of persons with acute hepatitis B report a history of incarceration (6). Hepatitis B vaccination of prisoners would prevent ongoing HBV transmission among inmates in prison facilities and after they have been released into the community. Because of the high proportion of inmates with previous risk factors for HBV infection and the difficulty in ascertaining current risk factors, experts in correctional health recommend vaccination of all inmates (7).

Some states have implemented successfully routine hepatitis B vaccination of prisoners. However, identifying resources to purchase and administer vaccine remains the major barrier to national implementation of this strategy. Partnerships between state health and corrections departments can help to implement hepatitis B vaccination and promote effective strategies for prevention of other STDs and infections in correctional facilities (8).

References

- 1. Hull HF, Lyons LH, Mann JM, et al. Incidence of hepatitis B in the penitentiary of New Mexico. Am J Public Health 1985;75:1213–4.
- Decker MD, Vaughn WK, Brodie JK, et al. The incidence of hepatitis B in Tennessee prisoners. J Infect Dis 1985;152:214–7.

Hepatitis B Outbreak — Continued

- 3. CDC. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR 1991;40(no. RR-13).
- 4. Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989;262:1201–5.
- 5. Bernier RH, Sampliner R, Gerety R, et al. Hepatitis B infection in households of chronic carriers of hepatitis B surface antigen. J Epidemiol 1982;116:199–211.
- Khan A, Goldstein S, Williams I, et al. Opportunities for hepatitis B prevention in correctional facilities and sexually transmitted disease treatment settings (Abstract). Antiviral Therapy 2000;5:21–2.
- National Commission on Correctional Health Care. Management of hepatitis B virus in correctional facilities. Chicago, Illinois: National Commission on Correctional Health Care, 1997.
- Association of State and Territorial Health Officials. Hepatitis C and incarcerated populations: the next wave for correctional health initiatives. Washington, DC: Association of State and Territorial Health Officials, 2000.

Influenza and Pneumococcal Vaccination Levels Among Persons Aged <u>>65</u> Years — United States, 1999

Annual influenza epidemics have resulted in an average of >18,000 deaths and 48,000 pneumonia and influenza hospitalizations among older persons in the United States (1). In 1998, an estimated 3400 older persons died from bacteremic pneumococcal pneumonia, a common complication of influenza, or from other forms of invasive pneumococcal disease (2). A 2000 national health objective included increasing influenza and pneumococcal vaccination levels to >60% among noninstitutionalized, high-risk persons, including those aged \geq 65 years (3). To assess progress toward this objective, data were analyzed from the 1999 Behavioral Risk Factor Surveillance System (BRFSS) for persons aged \geq 65 years. This report summarizes the results of that analysis, which indicated that prevalence of influenza vaccination during the 1998–99 influenza season exceeded the objective nationally and in 48 of 52 reporting areas; however, influenza vaccination levels may have reached a plateau. Prevalence among older persons who had ever received pneumococcal vaccination exceeded the national objective in only eight states. To reach the 2010 national objective of >90% influenza and pneumococcal vaccination among this population, new strategies and additional resources to implement adult vaccination activities may be needed.

BRFSS is an ongoing, state-based, random-digit-dialed telephone survey of noninstitutionalized civilian adults aged \geq 18 years. Questions about having received an influenza vaccination ("During the past 12 months, have you had a flu shot?") and pneumococcal vaccination ("Have you ever had a pneumonia vaccination?") were asked in odd-numbered years starting in 1993. In 1999, 30,668 of 159,989 respondents reported they were aged \geq 65 years. Respondents who reported an unknown influenza (2%) or pneumococcal (4%) vaccination status were excluded from analysis. Overall vaccination levels were estimated for the 50 states and the District of Columbia; data for Puerto Rico were reported in area-specific results only. Data were weighted by age, sex, and, in some states, by race/ethnicity, to reflect each area's estimated adult population. SUDAAN was used to calculate point estimates and 95% confidence intervals (CI), and to conduct multivariate logistic regression to calculate odds ratios (OR) and test associations of vaccination status with age, race/ethnicity, sex, education level, length of time since last check-up, self-reported health, and diabetes status.

Influenza and Pneumococcal Vaccination Levels - Continued

During 1999, 66.9% (95% CI=66.0%–67.8%) of respondents reported having received an influenza vaccination during the preceding year (Table 1), compared with 65.5% (95% CI=64.6%–66.4%) in 1997 (4). Estimated influenza vaccination levels exceeded 60% in 48 of 52 reporting areas; in 33 of 48, the lower limit of the 95% CI also exceeded 60% (Table 2). In three of four areas with point estimates of influenza vaccination below 60%, the 95% CI included 60%. Estimated influenza vaccination levels increased in 31 areas from 1997 to 1999, compared with increases in 48 areas from 1995 to 1997. In the 52 reporting areas, the median percentage point difference from 1997 to 1999 was 1.6 (range: –5.0– 9.0), compared with a median difference of 6.0 (range: –4.1–23.2) from 1995 to 1997.

		Influen	za		Pneumoco	ccal
			% point difference			% point difference
Characteristic	%	(95% CI*)	1997 to 1999	%	(95% CI)	1997 to 1999
Age group (yrs)						
65–74	63.4	(62.2–64.6)	0.2	49.9	(48.6–51.2)	8.2 [†]
<u>></u> 75	72.5	(71.2–73.8)	3.4 [†]	60.9	(59.4–62.2)	9.5 [†]
Race/Ethnicity						
Non-Hispanic white	69.0	(68.0–70.0)	1.8	56.8	(55.8–57.8)	9.6 ⁺
Non-Hispanic black	48.1	(44.4–51.8)	-2.1	36.4	(32.6–40.0)	6.7
Hispanic	58.6	(52.8–64.4)	0.7	34.6	(29.2–40.0)	0.5
Other⁵	68.3	(61.4–75.2)	4.0	51.7	(43.8–59.6)	9.1
Sex						
Men	68.2	(66.6–69.6)	1.1	53.6	(52.0-55.2)	8.5
Women	66.1	(65.0–67.2)	1.7	54.5	(53.4–55.8)	8.9 [†]
Education level						
Less than high school	60.5	(58.6–62.6)	0.4	46.8	(44.8-48.8)	6.7 ⁺
High school graduate	65.9	(64.4–67.4)	1.0	53.8	(52.2-55.4)	8.8 ⁺
More than high school	71.4	(70.0–72.8)	1.9	58.8	(57.2-60.2)	9.6 [†]
Length of time since last check-up						
1–12 months	69.9	(69.0–71.0)	1.1	57.1	(56.0–58.2)	8.8†
>1 year	48.2	(45.4–50.8)	1.0	36.3	(33.8–38.8)	7.0 [†]
Self-reported health						
Very good or excellent	65.5	(64.0–67.0)	2.6	51.4	(49.8–53.0)	9.2 [†]
Good	67.3	(65.8–69.0)	1.0	55.1	(53.4–56.8)	10.2 ⁺
Fair	68.6	(66.6–70.6)	1.9	56.6	(54.4–58.8)	8.2 [†]
Poor	69.4	(66.4–72.2)	-1.6	57.9	(54.6–61.2)	3.4
Diabetes						
Yes	72.6	(70.2–75.0)	3.7	59.3	(56.6–62.0)	9.1
Νο	66.1	(65.0–67.0)	1.0	53.3	(52.2–54.4)	8.6
Mean	66.9	(66.0–67.8)	1.5	54.1	(53.2–55.1)) <i>8.8</i> †

TABLE 1. Percentage of persons aged ≥65 years who reported receiving influenza or pneumococcal vaccine, by selected characteristics — Behavioral Risk Factor Surveillance System, United States, 1999

*Confidence interval.

⁺ Cls for 1997 and 1999 estimates do not overlap.

[§] Numbers for other racial/ethnic groups were too small for meaningful analysis.

Influenza and Pneumococcal Vaccination Levels — Continued

		Influenza			Pneumococ	cal
			% point difference			% point difference
Reporting area	%	(95% CI*)	1997 to 1999	%	(95% CI)	1997 to 1999
Alabama	64.6	(59.8–69.4)	2.1	53.9	(48.8–59.0)	6.4
Alaska	59.8	(48.7–70.8)	1.5	43.8	(33.0–54.6)	4.5
Arizona	71.3	(65.4–77.3)	-1.6	53.4	(46.8–60.0)	-6.0
Arkansas	67.3	(63.0–71.5)	6.2	50.2	(45.6–54.7)	11.1
California	72.2	(68.1–76.3)	6.7	57.0	(52.4–61.6)	7.1
Colorado	74.8	(69.2–80.3)	0.3	62.7	(56.6–68.9)	9.4
Connecticut	64.8	(59.8–69.8)	-2.5	49.0	(43.7–54.2)	5.9
Delaware	67.7	(62.2–73.2)	-0.9	66.5	(61.0–72.0)	13.9
District of Columbia	55.8	(49.1–62.6)	1.6	35.3	(28.8–41.7)	3.0
Florida	63.3	(59.8–66.8)	1.0	53.5	(50.2–57.0)	8.0
Georgia	57.0	(50.7–63.2)	-1.5	49.7	(43.3–56.1)	1.2
Hawaii	74.1	(68.0-80.2)	3.0	55.8	(49.0-62.6)	4.1
ldaho	69.0	(65.4–72.6)	2.5	55.2	(51.3–59.0)	5.0
Illinois [†]	67.5	(61.3–73.8)	-0.3	47.4	(40.6–54.1)	2.7
Indiana	66.2	(58.5-73.8)	3.6	51.6	(43.5-59.8)	13.6
lowa	69.6	(66.0-73.1)	-0.1	61.2	(57.4 - 65.0)	9.8
Kansas	67.0	(63.5–70.5)	5.6	55.1	(51.3–58.8)	11.4
Kentucky	68.4	(65.4–71.3)	7.1	52.0	(48.7-55.3)	13.4
Louisiana	60.3	(54.3–66.3)	1.9	40.4	(34.3–46.4)	8.1
Maine	73.7	(68.4–79.0)	1.6	57.3	(51.4–63.1)	7.3
Maryland	62.6	(57.7–67.4)	-0.9	54.1	(49.1–59.2)	13.1
Massachusetts	69.4	(65.7–73.1)	3.3	56.8	(52.7–60.8)	4.0
Michigan	70.0	(65.5–74.5)	6.4	57.7	(52.8–62.7)	12.1
Minnesota	64.0	(60.6–67.4)	-5.0	51.9	(48.2–55.5)	3.6
Mississippi	62.8	(57.5–68.1)	1.7	50.4	(44.8–55.9)	4.5
Missouri	68.4	(64.3–72.5)	-1.9	52.8	(48.4–57.2)	8.5
Montana	72.9	(68.1–77.7)	4.5	61.2	(55.7–66.6)	10.3
Nebraska	69.2	(65.4–72.9)	3.4	54.8	(50.9–58.8)	5.0
Nevada	62.2	(53.9–70.4)	5.6	61.7	(53.3–70.1)	8.2
New Hampshire	65.1	(58.2–72.0)	0.5	60.4	(53.1–67.6)	10.7
New Jersey	65.3	(60.7–69.9)	4.6	55.1	(50.2–60.0)	21.1
New Mexico	68.8	(64.8–72.8)	-4.0	53.2	(48.7–57.8)	3.1
New York	63.8	(58.8–68.8)	-0.6	50.0	(44.7–55.2)	11.0
North Carolina	64.2	(59.6–68.7)	-0.4	58.5	(53.8–63.3)	7.9
North Dakota	67.2	(62.6–71.8)	2.4	55.0	(50.1–59.9)	14.2
Ohio	68.8	(63.6–74.1)	3.5	55.0	(49.3–60.7)	16.4
Oklahoma	71.8	(68.0–75.7)	2.5	53.7	(49.5–57.9)	13.3
Oregon [§]	65.2	(59.7–70.6)	-4.7	56.2	(50.5–61.9)	0.3
Pennsylvania	63.1	(59.1–67.1)	-2.6	52.2	(48.1–56.4)	5.2
Puerto Rico	40.3	(36.2–44.4)	-1.2	21.8	(18.3–25.3)	-12.0
Rhode Island	75.8	(72.4–79.2)	8.1	56.9	(53.0–60.9)	13.9
South Carolina	69.9	(65.7–74.2)	-4.4	56.1	(51.4–60.8)	14.5
South Dakota	73.6	(70.6–76.6)	8.1	50.4	(46.9–53.9)	9.7
Tennessee	65.5	(61.1–69.9)	-3.6	54.3	(49.6–59.0)	9.3
Texas	69.8	(65.9–73.8)	1.8	55.9	(51.5–60.2)	11.4
Utah	75.1	(70.4–79.9)	9.0	55.9 61.3	(55.9–66.7)	11.4
Vermont	73.4	(69.7–77.2)	4.0	56.5	(52.1–60.9)	4.8
Virginia	65.7	(60.4–70.9)	-2.0	55.2	(49.7–60.8)	4.8 1.6
Washington						
J.,	68.9	(64.8–73.1)	-1.3	55.8	(51.4–60.3)	4.3
West Virginia	62.9	(58.7–67.0)	4.7	54.3	(50.0–58.6)	13.0
Wisconsin	64.9	(59.8–70.0)	-1.2	53.7 61 5	(48.3–59.1)	11.1
Wyoming	73.8	(69.2–78.5)	1.4	61.5	(56.3–66.7)	10.6
Range		3–75.8			8–66.5	
Median	6.	7.4		5	4.9	

TABLE 2. Percentage of persons aged \geq 65 years who reported receiving influenza or pneumococcal vaccine, by reporting area and type of vaccine — Behavioral **Risk Factor Surveillance System, United States, 1999**

*Confidence interval.

[†]A dual design was used and vaccination questions were asked of only half of the respondents. [§]Includes data from first quarter of 1999 interviews only.

Influenza and Pneumococcal Vaccination Levels - Continued

The proportion of respondents reporting having ever received a pneumococcal vaccination increased from 45.4% (95% CI=44.4%–46.3%) in 1997 to 54.1% (95% CI=53.2%–55.1%) in 1999 (Table 1). Estimated prevalence of pneumococcal vaccination was \geq 50% in 45 states and \geq 60% in eight states (Table 2). In one of the eight states with point estimates \geq 60%, the lower 95% CI also exceeded 60%. In 16 of 44 areas with estimated prevalence <60%, the 95% CI included 60%. From 1997 to 1999, pneumococcal vaccination prevalence estimates increased in 49 areas (median percentage point difference among the 52 reporting areas: 8.4; range: –12.0–21.1).

Non-Hispanic black and Hispanic respondents were significantly less likely than non-Hispanic white respondents to report vaccination against influenza (blacks: OR=0.41; 95% Cl=0.35–0.48, and Hispanics: OR=0.68; 95% Cl=0.53–0.88) or pneumococcal disease (blacks: OR=0.44; 95% Cl=0.37–0.53, and Hispanics: OR=0.43, 95% Cl=0.34–0.56) based on the logistic regression analysis (p<0.05). These differences were not explained by variations in age, sex, education level, length of time since last check-up, self-reported health, or diabetes status. A significant change in vaccination coverage from 1997 to 1999 among racial/ethnic populations was an increase in pneumococcal vaccination among non-Hispanic whites (Table 1).


Other factors independently associated with vaccination status based on the logistic regression analysis were age, education level, length of time since last check-up, and health status (p<0.05). Persons aged \geq 75 years were more likely to report influenza or pneumococcal vaccination than persons aged 65–74 years (Table 1). Persons with diabetes were more likely to report vaccination, compared with those who did not have diabetes. Coverage increased as education level increased, self-reported health declined, and length of time since last check-up decreased.

Reported by the following BRFSS coordinators: S Reese, MPH, Alabama; P Owen, Alaska; B Bender, MBA, Arizona; G Potts, MBA, Arkansas; B Davis, PhD, California; M Leff, MSPH, Colorado; M Adams, MPH, Connecticut; F Breukelman, Delaware; I Bullo, District of Columbia; S Hoecherl, Florida; L Martin, MS, Georgia; F Reyes-Salvail, MS, Hawaii; J Aydelotte, MA, Idaho; B Steiner, MS, Illinois; L Stemnock, Indiana; J Davila, MS, Iowa; C Hunt, Kansas; T Sparks, Kentucky; B Bates, MSPH, Louisiana; D Maines, Maine; A Weinstein, MA, Maryland; D Brooks, MPH, Massachusetts; H McGee, MPH, Michigan; N Salem, PhD, Minnesota; D Johnson, MS, Mississippi; J Jackson-Thompson, PhD, Missouri; P Feigley, PhD, Montana; L Andelt, PhD, Nebraska; E DeJan, MPH, Nevada; L Powers, MA, New Hampshire; G Boeselager, MS, New Jersey; W Honey, MPH, New Mexico; C Baker, New York; Z Gizlice, PhD, North Carolina; L Shireley, MPH, North Dakota; P Pullen, Ohio; K Baker, MPH, Oklahoma; K Pickle, MPH, Oregon; L Mann, Pennsylvania; Y Cintron, MPH, Puerto Rico; J Hesser, PhD, Rhode Island; M Wu, MD, South Carolina; M Gildmaster, South Dakota; D Ridings, Tennessee; K Condon, MS, Texas; K Marti, Utah; C Roe, MS, Vermont; K Carswell, MPH, Virginia; K Wynkoop-Simmons, PhD, Washington; F King, West Virginia; K Pearson, Wisconsin; M Futa, MA, Wyoming. A Poel, Association of Schools of Public Health, Atlanta, Georgia. Statistical Analysis Br, Data Management Div, and Adult Vaccine-Preventable Diseases Br, Epidemiology and Surveillance Div, National Immunization Program, CDC.

Editorial Note: The findings in this report indicate that by 1999 coverage levels among persons aged \geq 65 years approached or exceeded the 2000 national objective for influenza vaccination in all states and for pneumococcal vaccination in 24 states. Pneumococcal vaccination coverage increased linearly from 1993 to 1999; the rate of increase for influenza vaccination coverage was lower from 1997 to 1999 than from 1993 to 1997 (Figure 1). Similar findings were observed in the 1993–1998 National Health Interview Surveys (NHIS), which monitors progress toward the national health objectives (*5*; CDC, unpublished data, 2000). Self-reported influenza vaccination in the

Influenza and Pneumococcal Vaccination Levels — Continued





1999 BRFSS mainly reflected vaccinations received for the 1998–99 influenza season. Vaccination coverage for subsequent seasons will be monitored using BRFSS and NHIS to determine whether influenza vaccination coverage for this population reached a plateau by the 1999–2000 season and the effect of delays in influenza vaccine supply during the 2000–01 season and projected for 2001–02. Preliminary NHIS estimates of influenza vaccination coverage among older adults were 66.6% for those interviewed during the first 6 months of 1999 and 68.1% for the first 6 months of 2000 (http:// www.cdc.gov/nchs/nhis.htm).

In addition to increasing influenza and pneumococcal vaccination to \geq 90% among persons aged \geq 65 years by 2010, another national health objective is to eliminate health disparities among diverse populations (6). Racial/ethnic disparities continued in vaccination levels from 1997 to 1999. Influenza vaccination levels were lower among persons with less than a high school education or aged 65–74 years than among persons with higher education levels or older age.

Pneumococcal vaccination coverage lagged behind influenza vaccination coverage and was <60% even among persons most likely to visit a health-care provider (e.g., those reporting a check-up within the preceding 12 months, poor health, or diabetes). Healthcare providers should use every opportunity to assess the vaccination status of patients and offer indicated vaccines. Annual influenza vaccination provides such an opportunity; influenza and pneumococcal vaccines can be administered concurrently at different sites without increasing side effects, and pneumococcal vaccine should be administered to patients who are uncertain about their vaccination history (5).

The findings in this report are subject to at least two limitations. First, vaccination status was self-reported and not validated; self-report of influenza vaccination may be more reliable than self-report of pneumococcal vaccination (7). In addition, recall of pneumococcal vaccination may be more accurate for persons aged 65–74 years than for those aged \geq 75 years (8). Second, BRFSS excludes nursing-home residents and other institutionalized populations and households without telephones or with only cellular phones; however, vaccination coverage among older adults estimated from the 1997 NHIS increased only slightly when households without telephones were excluded (from 63.2% to 64.1% for influenza and from 42.4% to 43.0% for pneumococcal) (CDC, unpublished data, 2000).

Influenza and Pneumococcal Vaccination Levels - Continued

Multiple factors underscore the need to assess local, state, and national adult vaccination programs (9), including a possible plateau in influenza vaccination levels among older adults, failure nationally and in most states to meet the 2000 objective for pneumococcal vaccination, racial/ethnic and socioeconomic disparities in vaccination coverage, delays in the distribution of the influenza vaccine reported during the 2000–01 season (1,5), and projected delays during 2001–02 (http://www.cdc.gov/nip/flu/acip-june21.htm). To achieve and sustain \geq 90% vaccination among these populations, public, private, and community partners must collaborate to improve vaccine use among older persons and to strengthen the influenza vaccine supply. When supply problems are anticipated, delivery of the first available vaccine should target older persons and others at high risk; for the 2001–02 season, providers should target vaccine available in September and October to these groups and to health-care workers. Physicians can improve coverage using strategies such as provider reminder/recall, assessment and feedback, and standing orders (10); however, methods are needed to identify and increase the number of healthcare providers using these strategies. Even with such strategies, providers may be unable to achieve the 2010 objective among older patients during October-November, the optimal period for influenza vaccination. Providers should continue to vaccinate through December and as long as vaccine is available. Other interventions include increasing community demand for vaccinations using client reminder/recall and education campaigns (10), enhancing access to vaccination services by reducing out-of-pocket costs (10), and offering vaccination in community settings such as senior centers and drug stores.

References

- CDC. Updated recommendations from the Advisory Committee on Immunization Practices in response to delays in supply of influenza vaccine for the 2000–01 season. MMWR 2000;49:888–92.
- 2. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive *Streptococcus pneumoniae* infections in the United States, 1995–1998. JAMA 2001;285:1729–35.
- Public Health Service. Healthy people 2000: national health promotion and disease prevention objectives—healthy people 2000 review 1998–1999. Washington, DC: US Department of Health and Human Services, Public Health Service, 1999; DHHS publication no. (PHS)99-1256.
- CDC. Influenza and pneumococcal vaccination levels among adults aged ≥65 years— United States, 1997. MMWR 1998;47:797–802.
- 5. CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2001;50(no. RR-4).
- 6. US Department of Health and Human Services. Healthy people 2010 (conference ed., 2 vols). Washington, DC: US Department of Health and Human Services, 2000.
- 7. MacDonald R, Baken L, Nelson A, Nichol KL. Validation of self-report of influenza and pneumococcal vaccination status in elderly outpatients. Am J Prev Med 1999;16:173–7.
- Long C, Kouides R, Peer S, LaForce F, Whitney C, Bennett N. Accuracy of self-report of pneumococcal vaccine status in older adults. Abstracts of the 127th American Public Health Association Meeting, November 7–11, 1999. Chicago, Illinois: American Public Health Association, 1999.
- Guyer B, Smith DR, Chalk R. Calling the shots: immunization finance policies and practices. Executive summary of the report of the Institute of Medicine. Am J Prev Med 2000;19(3S):4–12.
- Task Force on Community Preventive Services. Recommendations regarding interventions to improve vaccination coverage in children, adolescents, and adults. Am J Prev Med 2000;18(1S):92–6.

Routinely Recommended HIV Testing at an Urban Urgent-Care Clinic — Atlanta, Georgia, 2000

In 1993, CDC recommended that hospitals and associated clinics in areas with high human immunodeficiency virus (HIV) prevalence offer HIV testing routinely to all patients aged 15-54 years (1). Although voluntary routine screening among hospitalized (2) and emergency department patients (3) can identify many undiagnosed HIVinfected persons, few screening programs have been implemented in these settings. A 1997 study at Grady Memorial Hospital, Atlanta, Georgia, found that nearly two thirds of inpatients newly diagnosed with acquired immunodeficiency syndrome (AIDS) had received medical care within the Grady health system during the 12 months preceding admission* (4); these previous encounters were missed opportunities for earlier diagnosis of HIV. In response to the 1997 study, investigators studied routinely recommending HIV testing to patients presenting to the urgent-care clinic, an ambulatory clinic that provides episodic medical care to indigent and low income adults. This report summarizes the results of that study in which, compared with 1999 when testing was based on symptoms or risk behaviors, more patients were tested for HIV, more HIV infections were detected, and more infected persons learned their diagnosis and entered into care. These results reflect the benefits of recommending HIV testing routinely to patients in medical facilities located in areas with high HIV prevalence.

For 24 weeks (i.e., March 20-September 1, 2000), clinicians were encouraged to recommend HIV testing to all urgent-care clinic patients aged 18-65 years who were neither known to be HIV seropositive[†] nor tested during the preceding 6 months. These 24 weeks were compared with testing during the same 24 weeks in 1999, when HIV testing was conducted only when clinicians were concerned about patients' symptoms or risk behaviors. During the study period, posters encouraging patients to be tested for HIV were displayed prominently, and patients received a brochure about HIV and HIV testing before discussions with their heath-care providers. Patients who accepted testing provided written consent and were not charged for HIV testing, which was conducted with either a rapid test (Single Use Diagnostic System [SUDS] HIV-1 Test [Abbott-Murex] Corporation, Norcross, Georgia]) or a standard enzyme immunoassay (EIA). All SUDS tests were supplemented with EIA; all positive SUDS and EIA tests were confirmed with Western blot. Clinicians, counselors, or study investigators trained in HIV counseling delivered test results; a physician's assistant telephoned or wrote to HIV-seropositive persons who had left before their SUDS results were available or who did not return to the clinic for their EIA result. The study was approved by the human subjects research committees of CDC, Emory University, and the Grady Research Oversight Committee.

Patients were defined as knowing their test result if discussion of results was documented in the medical record or clinic HIV testing log or if patients had a CD4 test within 2 months after their positive HIV test. Entry into care was defined by a record of a visit to the Grady infectious disease clinic within 4 months following the positive HIV test.

Approximately 20,000 clinic visits occurred during each of the two periods (i.e., 1999 and 2000) (Table 1). Comparing 2000 with 1999, 1687 more patients were tested, 27 more infections were newly detected, 27 more patients were informed of their HIV-

^{*}Median of four visits per patient; the most frequented departments were the emergency department and the urgent-care clinic.

[†] Based on patient interview and medical record review.

Routinely Recommended HIV Testing — Continued

s Test process	Risk- and ymptom-based testing 1999 No.	Routinely recommend testing 2000 No.		Ratio	p value
Clinic visits	19,626	19,911	285	1.0	<u> </u>
HIV tests conducted	1,100	2,787	1,687	2.5	<0.001
Newly detected infection	ns* 47	74	27	1.6	0.02
HIV-positive patients whe	cted [†] 28	55	27	2.0	0.004
HIV-positive patients whe entered into care [§]	o 13	26	13	2.0	0.04

TABLE 1. Number of persons tested for HIV based on risk and symptoms during 24 weeks in 1999 compared with the number of persons routinely recommended for HIV testing in 2000 at an urgent-care clinic — Atlanta, Georgia, March 20–September 1, 1999, and 2000

*Positive HIV test result (Western blot).

⁺ Evidence that patient was informed of HIV-positive test result (i.e., documentation in the medical record or clinic HIV testing log of delivery of results to patient or evidence of CD4 test within the Grady health system within 2 months after the positive HIV test).

[§] Record of patient visit to the Grady infectious disease clinic within 4 months following the positive HIV test.

positive test result, and twice as many HIV-seropositive patients (26 versus 13) entered into care[§] (Table 1). During the study, infected persons may have had HIV detected at an earlier stage of infection; 28 (67%) of 42 persons had a CD4+ T cell count >200 cells/ μ L during the study period compared with 10 (45%) of 22 during 1999 (p=0.1). Additional information on HIV test eligibility, provider recommendations, and testing patterns was collected from 8 a.m. to 5 p.m. weekdays during the study period[¶]. Among the 13,039 patient visits to the urgent-care clinic during these hours, 10,719 were eligible to be offered HIV testing. Among those eligible, 6421 (60%) were offered testing and 2564 (40%) accepted. Among those who accepted testing, 1839 (72%) were actually tested. Among 886 patients tested with SUDS, 236 (27%) received results the same day.

Reported by: C Del Rio, MD, C Franco Paredes, MD, W Duffus, MD, K Cesarz, S Green, G Hicks, MPH, M Barragan, MPH, Grady Memorial Hospital, Atlanta, Georgia. Div of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention; and an EIS Officer, CDC.

Editorial Note: HIV testing usually relies on a patient's request or a health-care provider's concern about symptoms or risk behaviors. This report indicates that when providers at an urgent-care clinic in a high prevalence area routinely recommended HIV testing, more persons were tested, more HIV infections were detected, and more patients with newly detected infections learned their diagnosis and entered into care. Patients often were diagnosed earlier in the course of their infection.

Despite the benefits of routinely recommended testing, barriers to this approach exist, as demonstrated by the proportion of patients who were not offered testing, did not accept testing, and were not tested once they had accepted. In addition, 26% of patients

[§] This intervention was neither designed nor expected to improve the proportion of infected persons who entered into care; the proportion was approximately the same for the two periods (i.e., 13 [46%] of 28 in 1999 and 26 [47%] of 55 in 2000).

[¶] Urgent-care clinic hours during 1999 and 2000 were Monday–Friday from 8 a.m. to 10 p.m. and weekends from 9 a.m. to 7 p.m.

Routinely Recommended HIV Testing — Continued

with newly detected infections did not learn their HIV-positive diagnosis, and 53% of those who learned their diagnosis did not enter into medical care.

The findings in this report are subject to at least four limitations. First, some newly diagnosed patients may have sought care from providers outside the Grady health system (e.g., private providers or other public health facilities) and would not have been recorded as having received care. Second, the large proportion of patients tested during both periods for whom CD4 count data were unavailable limited the comparison of the stage of infection among patients diagnosed in 1999 with those diagnosed in 2000. Third, the proportions of patients who were eligible for, offered, accepted, and were actually tested from 8 a.m. to 5 p.m. weekdays may have differed from the 1999 comparison period or other study hours. Finally, no data were available to evaluate whether characteristics of the clinic population changed between comparison periods.

The findings in this study suggest some strategies clinics can use to increase the acceptance, feasibility, and effectiveness of routinely recommended testing. To increase the numbers of patients providers recommend for testing, providers must be convinced that time demands will not be excessive; to increase the number of patients who accept testing, patients must believe that HIV testing and the subsequent results are relevant. HIV risk can be assessed quickly using screening questions, and patients can be referred for client-centered prevention counseling when necessary (5). In this study, posters and brochures provided basic HIV test information and helped providers focus on issues specific to the individual patient. Rapid tests that could be performed in the clinic rather than a hospital laboratory and that could use either oral fluids or whole blood obtained by fingerstick** might increase the acceptability of HIV testing and the number of patients that receive test results in a clinic. In addition, medical centers must develop clear, concise strategies that would facilitate medical care and prevention counseling for newly diagnosed patients. Convenient and efficient links to HIV medical care are benefits to having HIV testing in a clinic; however, informing patients of their diagnosis is insufficient to ensure that they will receive HIV-specific medical care.

Testing for HIV infection in high HIV prevalence areas has become more important and more feasible since 1993. Medical therapy now can reduce substantially HIV-related morbidity and mortality, prevention counseling can help HIV-infected persons protect their partners by adopting safer behaviors, and earlier HIV diagnosis increases the benefits of both treatment and prevention (6). Approximately 300,000 HIV-infected persons in the United States may not know that they are infected (7), and missed opportunities for earlier diagnosis of HIV frequently occur in medical settings (4).

Recommending HIV testing routinely in clinical settings presents an opportunity to target high prevalence communities, destigmatize HIV testing, and better link HIV-infected persons to care and prevention services. Counseling and testing are potentially cost saving because they can reduce transmission (8); however, institutions are unlikely to absorb these costs. Public health departments and other HIV prevention programs can assist with financial and/or human resources in implementing routinely recommended HIV testing at clinics in high HIV prevalence areas. Health departments and administrators of clinical facilities in such areas are encouraged to adopt a policy of routinely recommending HIV testing.

^{**} Such tests would eliminate the need to wait for a phlebotomist, have blood drawn, and return for a second visit to receive test results. SUDS, the only rapid HIV test licensed in the United States, is labor intensive, and most patients tested with SUDS in this study did not receive their SUDS result on the same day that it was performed.

Routinely Recommended HIV Testing — Continued

References

- 1. CDC. Recommendations for HIV testing services for inpatients and outpatients in acutecare hospital settings. MMWR 1993;42(no. RR-2).
- 2. Irwin K, Olivo N, Schable CA, et al. Performance characteristics of a rapid HIV antibody assay in a hospital with a high prevalence of HIV infection. Ann Intern Med 1996;125:471–5.
- Kelen GD, Shahan JB, Quinn TC. Emergency department-based HIV screening and counseling: experience with rapid and standard serologic testing. Annals of Emerg Med 1999; 33:147–55.
- Alexander L, Sattah M, Ziemer DB, Del Rio C. Missed opportunities for HIV diagnosis at an inner city hospital in the United States [Abstract 43131]. Presented at the XII International Conference on AIDS, Geneva, Switzerland, June 28–July 3, 1998.
- 5. CDC. HIV counseling, testing and referral standards and guidelines. Atlanta, Georgia: US Department of Health and Human Services, Public Health Service, 1994.
- 6. Valdiserri RO, Holtgrave DR, West GR. Promoting early HIV diagnosis and entry into care. AIDS 1999;13:2317–30.
- CDC. CDC guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. MMWR 1999;48(no. RR-13).
- 8. Varghese B, Peterman TA, Holtgrave DR. Cost-effectiveness of counseling and testing and partner notification: a decision analysis. AIDS 1999;13:1745–51.

542




FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals ending June 23, 2001, with historical data

* No measles cases were reported for the current 4-week period yielding a ratio for week 25 of zero (0).

[†] Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

		Cum. 2001		Cum. 2001
Anthrax		-	Poliomyelitis, paralytic	-
Brucellosis*		31	Psittacosis*	6
Cholera		2	Q fever*	7
Cyclosporiasis	*	71	Rabies, human	-
Diphtheria		1	Rocky Mountain spotted fever (RMSF)	122
Ehrlichiosis:	human granulocytic (HGE)*	32	Rubella, congenital syndrome	-
	human monocytic (HME)*	18	Streptococcal disease, invasive, group A	1,868
Encephalitis:	California serogroup viral*	-	Streptococcal toxic-shock syndrome*	31
·	eastern equine [×]	-	Syphilis, congenital [¶]	84
	St. Louis [*]	-	Tetanus	12
	western equine*	-	Toxic-shock syndrome	57
Hansen diseas	se (leprosy)*	29	Trichinosis	5
	Imonary syndrome* [†]	4	Tularemia*	30
Hemolytic ure	mic syndrome, postdiarrheal*	33	Typhoid fever	117
HIV infection,	pediatric* [§]	84	Yellow fever	-
Plaque	•	1		

TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending June 23, 2001 (25th Week)

-: No reported cases. *Not notifiable in all states.

¹Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP). Last update May 29, 2001. [§]Updated from reports to the Division of STD Prevention, NCHSTP.

									<i>coli</i> 0157:H7	
ŀ	All Cum.	DS Cum.	Chlan Cum.	nydia [†] Cum.	Cryptos Cum.	ooridiosis Cum.	NET Cum.	SS Cum.	PH Cum.	LIS Cum.
Reporting Area	2001 [§]	2000 18.050	2001 307,664	2000	2001 749	2000 730	2001 688	2000 1,082	2001 447	2000 923
NEW ENGLAND Maine N.H.	15,380 586 18 14	18,050 1,100 16 17	307,664 10,668 591 595	327,962 10,943 661 495	749 32 3 1	730 44 9 2	688 82 11 13	1,082 110 6 6	447 48 7 7	923 109 6 9
/t. Mass. R.I. Conn.	10 332 44 168	17 762 40 248	277 4,875 1,339 2,991	258 4,644 1,252 3,633	13 8 3 4	13 12 2 6	2 32 4 20	4 54 6 34	1 21 2 10	6 49 8 31
MID. ATLANTIC Jpstate N.Y. N.Y. City N.J. Pa.	3,108 182 1,587 746 593	4,466 426 2,451 896 693	33,512 5,709 13,895 4,548 9,360	31,093 530 13,390 5,766 11,407	85 37 42 3 3	139 35 80 5 19	55 41 4 10 N	130 91 9 30 N	38 25 3 10	96 38 7 26 25
E.N. CENTRAL Dhio nd. II. Mich. Wis.	1,163 198 119 558 224 64	1,604 196 146 1,003 191 68	43,899 5,821 6,783 12,222 14,361 4,712	56,472 14,597 6,259 16,357 11,345 7,914	230 51 29 1 63 86	161 22 11 22 24 82	168 51 28 33 26 30	209 32 22 63 33 59	99 33 11 19 19 17	140 32 24 40 26 18
W.N. CENTRAL Minn. owa Mo. V. Dak. S. Dak. Yebr.	355 67 40 168 1 9 27	382 86 36 151 1 3 25	15,912 2,876 1,490 5,764 464 870 1,571	18,449 3,810 2,389 6,300 440 851 1,748	66 24 20 7 3 4 8	55 11 15 8 5 5 8	85 30 15 17 1 6 7	135 38 22 33 7 7 19	74 37 7 18 3 5	148 50 23 34 6 11 18
Kans. S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	43 4,910 84 591 360 388 35 212 340 579 2,321	80 4,778 78 592 317 316 27 310 374 430 2,334	2,877 59,478 1,405 5,759 1,593 8,351 1,112 8,083 5,535 11,691 15,949	2,911 60,295 1,402 6,243 1,541 7,620 1,014 10,481 4,726 11,994 15,274	- 143 1 27 9 8 - 15 - 48 35	3 106 4 6 4 3 10 555 20	9 71 - 19 2 25 25 10 9	9 85 1 0 - 18 3 16 6 13 18	4 29 - U 8 - 11 2 2 6	6 71 - U 18 3 15 6 13 15
E.S. CENTRAL Ky. Fenn. Ala. Miss.	836 181 249 182 224	896 113 359 207 217	22,106 4,206 7,069 5,350 5,481	23,654 3,826 6,925 7,281 5,622	17 1 3 6 7	23 1 5 9 8	28 8 13 6 1	44 15 16 4 9	18 8 9 - 1	34 13 15 4 2
V.S. CENTRAL Ark. .a. Okla. ēx.	1,617 89 403 90 1,035	1,806 99 290 161 1,256	48,769 3,522 8,126 5,234 31,887	49,752 2,961 9,048 4,329 33,414	16 2 7 5 2	35 1 8 3 23	31 2 2 10 17	118 31 7 7 73	39 - 14 10 15	143 26 18 7 92
MOUNTAIN Mont. daho Vyo. Jolo. J. Mex. Ariz. Jtah Jev.	636 12 14 126 50 258 53 122	639 7 13 55 155 58 172 62 167	16,583 1,015 839 368 1,618 2,600 7,047 697 2,399	19,338 752 864 354 5,755 6,120 1,261 1,827	52 5 6 16 10 2 11 2	37 6 3 5 10 1 2 8 2	78 5 12 1 33 7 10 6 4	97 12 6 38 3 21 4 1	40 - 1 20 2 9 7 1	65 5 24 3 18 8 2
PACIFIC Wash. Dreg. Calif. Alaska Hawaii	2,169 247 104 1,787 9 22	2,379 244 86 1,965 5 79	56,737 6,568 1,447 46,927 1,261 534	57,966 6,191 3,387 45,507 1,199 1,682	- 108 N 5 101 - 2	130 U 7 123 -	90 23 17 47 1 2	154 50 22 73 1 8	62 13 13 34 - 2	117 66 27 16 1 7
Guam P.R. V.I. Amer. Samoa	9 535 2	13 431 21	2,154 53 U 55	243 U - U	- - - U	- - - U	N - - U	N 5 - U	U U U U	U U U U

 TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending June 23, 2001, and June 24, 2000 (25th Week)

N: Not rotifiable. U: Unavailable. -: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands. * Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS). * Chlamydia refers to genital infections caused by *C. trachomatis.* Totals reported to the Division of STD Prevention, NCHSTP. * Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last update May 29, 2001.

	Gono	ung June	Hepati Non-A,	tis C;	Legione		Listeriosis	Ly	me ease
Poporting Area	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.
Reporting Area	2001 138,907	2000 162,016	2001 1,059	2000 1,639	2001 332	2000 356	2001 190	2001 1,556	2000 4,039
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	2,908 65 64 38 1,483 345 913	3,032 35 52 29 1,196 308 1,412	14 - 6 8 -	14 1 3 7 3	19 1 5 4 4 1 4	23 2 1 10 3 5	24 - - 13 1 10	483 56 1 51 46 329	887 36 8 354 26 463
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	15,070 3,522 5,807 1,409 4,332	17,193 3,055 5,584 3,238 5,316	41 28 - 13	357 15 318 24	38 25 4 5 4	90 26 12 8 44	29 12 5 7 5	642 464 1 84 93	2,441 589 94 1,065 693
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	23,476 3,572 2,787 7,392 8,266 1,459	32,594 8,321 2,845 9,935 8,140 3,353	105 5 1 10 89	125 3 12 110	84 46 7 - 21 10	93 36 12 9 17 19	24 6 4 13 1	56 36 2 - 18	235 16 4 17 9 189
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	6,664 920 392 3,434 15 132 540 1,231	7,909 1,531 490 3,822 34 127 660 1,245	380 2 - 374 - 1 3	284 4 1 273 - 2 4	29 6 10 1 1 4 1	18 1 3 10 - 1 1 2	5 - 2 - 1 2	58 37 10 8 - 1 2	47 15 17 - 2 12
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	35,997 773 3,176 1,360 4,290 290 6,736 4,018 6,344 9,010	42,234 794 4,178 1,082 4,808 319 8,484 4,533 7,428 10,608	52 - 9 - 6 9 3 - 25	40 2 4 1 5 13 1 2 11	61 - 17 2 7 N 5 1 4 25	63 4 17 9 N 8 2 4 19	30 - - 5 4 - 2 9 8	245 15 158 7 45 1 7 2 -	345 65 215 1 40 8 9 2 - 5
E.S. CENTRAL Ky. Tenn. Ala. Miss.	14,055 1,626 4,598 4,321 3,510	16,788 1,600 5,321 5,651 4,216	108 3 31 2 72	230 17 55 7 151	32 7 15 8 2	11 5 3 2 1	8 2 3 3	10 2 5 3	16 4 9 2 1
W.S. CENTRAL Ark. La. Okla. Tex.	23,517 2,172 5,615 2,371 13,359	25,572 1,559 6,360 1,858 15,795	161 3 74 3 81	474 3 246 2 223	5 - 2 3 -	17 - 7 1 9	5 1 - 1 3	7 - 1 - 6	25 - 3 - 22
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	4,914 53 37 29 1,503 414 1,948 62 868	4,950 26 43 30 1,541 517 2,006 126 661	135 - 101 101 8 1 3	35 2 3 2 5 8 11 - 4	26 - 1 8 1 9 4 2	17 - - 6 1 2 5 -	20 - 1 3 5 4 1 5	5 - 2 1 - - - 1	2 - - - - - 1
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	12,306 1,408 223 10,373 167 135	11,744 1,085 424 9,857 156 222	63 16 8 39 -	80 10 16 54 -	38 6 N 31 - 1	24 8 N 16 -	45 3 1 40 - 1	50 2 3 45 N	41 - - 37 - 1 N
Guam P.R. V.I. Amer. Samoa C.N.M.I.	509 6 U 3	25 268 - U U	- 1 - U -	1 1 - U U	2 - U -	- - U U		N - U -	N U U

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States,
weeks ending June 23, 2001, and June 24, 2000 (25th Week)

N: Not notifiable. U: Unavailable. -: No reported cases.

	Weekse	nunig ou	10 20, 20					
	Ma	laria	Rabie	s, Animal	NE	TSS	nellosis* Pl	ILIS
Reporting Area	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000
UNITED STATES	424	549	2,719	3,138	12,232	14,303	9,222	12,678
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	31 3 - 9 3 14	22 4 1 2 9 4 2	288 34 7 36 94 27 90	346 69 4 32 112 16 113	973 101 76 35 512 56 193	856 59 56 52 507 32 150	806 74 65 34 393 67 173	880 38 59 51 501 58 173
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	79 19 40 14 6	119 26 60 16 17	399 305 11 76 7	549 329 5 72 143	1,306 441 414 295 156	2,145 485 562 545 553	1,485 376 470 218 421	2,188 555 573 424 636
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	45 9 10 1 17 8	67 8 3 35 15 6	29 13 1 4 11	35 6 - 1 20 8	1,753 606 177 397 333 240	2,059 494 234 652 393 286	1,232 412 141 255 275 149	1,278 464 251 1 415 147
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	16 6 1 5 - 2 2	24 7 5 2 - 3 6	161 18 35 13 24 21 1 49	279 38 39 14 74 57 57	760 211 129 202 14 52 55 97	935 206 117 307 27 35 87 156	750 279 95 247 22 39 - 68	1,052 286 127 362 37 43 70 127
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	120 1 48 9 24 1 2 4 8 23	121 3 39 8 26 - 11 1 4 29	986 18 115 62 284 60 135 99	1,093 20 213 58 282 59 123 63	2,900 35 317 33 469 48 437 313 417 831	2,402 42 318 26 347 60 337 212 385 675	1,642 33 262 U 328 48 272 272 272 351 76	2,075 55 314 U 353 59 337 176 588 193
E.S. CENTRAL Ky. Tenn. Ala. Miss.	11 2 6 3	19 5 5 8 1	91 10 62 19	89 12 47 30	709 127 207 229 146	700 150 166 195 189	416 81 187 109 39	564 110 246 175 33
W.S. CENTRAL Ark. La. Okla. Tex.	6 3 1 1 1	32 1 4 3 24	481 - 39 442	481 - 35 446	1,083 197 240 100 546	1,689 176 285 137 1,091	898 92 214 81 511	983 119 205 112 547
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	25 2 3 - 11 3 3 2	21 1 - 11 2 3 4	108 16 2 16 - 4 68 1 1	119 32 1 33 - 8 42 2 1	869 36 52 28 239 111 244 97 62	1,126 53 61 31 345 98 255 166 117	607 4 22 200 75 206 77 23	1,050 53 26 330 101 272 163 105
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	91 3 5 79 1 3	124 11 22 85 - 6	176 - 143 	147 2 122 23	1,879 202 87 1,498 21 71	2,391 199 152 1,930 24 86	1,386 205 125 930 2 124	2,608 278 194 2,025 20 91
Guam P.R. V.I. Amer. Samoa C.N.M.I.	3 - U -	- 4 - U U	61 U	32 U U	274 U 5	13 212 U U		U U U U U

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending June 23, 2001, and June 24, 2000 (25th Week)

N: Not notifiable. U: Unavailable. -: No reported cases. * Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

		Shige		.,		philis		
	NET			HLIS		k Secondary)	Tuber	rculosis
Reporting Area	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000
UNITED STATES	5,974	9,237	2,792	5,139	2,531	2,962	5,086	6,338
NEW ENGLAND Maine N.H. Vt. Mass. R.I.	100 4 2 3 65 7	159 5 1 114 10	86 1 2 52 11	147 6 101 13	24 1 2 13 3	43 1 29 3	197 5 10 2 107 19	185 3 4 3 113 17
Conn. MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	19 554 297 168 40 49	28 1,332 401 605 209 117	18 343 15 196 67 65	27 820 147 385 180 108	5 204 10 120 46 28	9 142 6 62 30 44	54 1,066 136 564 237 129	45 1,061 126 572 244 119
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	952 434 118 172 147 81	1,900 125 682 527 397 169	423 188 19 105 98 13	560 102 62 2 362 32	421 41 81 109 180 10	630 34 210 220 136 30	543 79 38 285 109 32	604 137 58 279 89 41
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. S. Dak. Nebr. Kans.	637 217 144 123 13 67 32 41	845 219 196 324 4 2 29 71	461 240 84 81 2 37 - 17	705 252 165 227 4 1 19 37	28 12 7 - - 8	40 4 10 21 - 2 3	196 100 18 52 3 6 17	231 78 19 83 2 9 10 30
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	943 4 54 23 75 4 183 106 103 391	1,062 7 53 13 157 3 59 59 115 596	260 4 26 27 6 78 46 57 16	423 7 23 U 160 3 32 49 92 57	960 5 112 20 63 - 224 130 135 271	961 5 142 20 67 1 281 102 166 177	1,036 9 33 15 110 14 158 100 173 364	1,265 3 117 7 133 17 175 144 258 411
E.S. CENTRAL Ky. Tenn. Ala. Miss.	602 228 44 125 205	444 120 202 27 95	223 96 38 78 11	289 45 220 21 3	280 22 156 51 51	440 48 273 59 60	318 42 99 129 48	433 53 166 141 73
W.S. CENTRAL Ark. La. Okla. Tex.	933 308 104 18 503	1,551 99 148 55 1,249	650 155 81 2 412	457 24 83 20 330	328 19 61 34 214	397 47 95 66 189	520 66 67 387	956 91 71 61 733
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	356 - 68 55 164 24 29	417 4 29 2 79 44 152 34 73	206 - 54 33 89 22 8	275 20 2 37 24 104 37 51	102 - - 20 9 63 6 4	104 - 1 5 9 85 1 3	178 - 4 1 53 11 65 9 35	227 6 4 1 31 28 82 22 53
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	897 81 29 771 3 13	1,527 315 94 1,091 6 21	140 76 46 - 1 17	1,463 277 59 1,106 3 18	184 30 4 148 - 2	205 35 8 161 - 1	1,032 97 46 847 21 21	1,376 111 41 1,098 59 67
Guam P.R. V.I. Amer. Samoa	6 - U	19 14 - U	U U U	U U U	129 Ū	2 88 U	51 Ū	28 70 U
C.N.M.I. N: Not notifiable.	4	U vailable.	U	U rted cases.	-	U	19	U

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States,
weeks ending June 23, 2001, and June 24, 2000 (25th Week)

N: Not notifiable. U: Unavailable. -: No reported cases. *Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

		and June 24, 2000 (25th Week)										
	-	ienzae,	H	epatitis (Vi	ral), By Ty	pe			Meas	les (Rubec		
	-	sive	Α	-	В		Indiger		Impo		Total	
Reporting Area	Cum. 2001 [†]	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	2001	Cum. 2001	2001	Cum. 2001	Cum. 2001	Cum. 2000
UNITED STATES	682	676	4,366	6,120	2,927	3,280	-	40	-	25	65	48
NEW ENGLAND	35	51	212	157	45	52	-	4	-	1	5	3
Maine N.H.	1	1 8	5 5	7 13	5 11	5 10	-	-	-	-	-	-
Vt.	1	3	6	4	2	5	-	1	-	-	1	3
Mass. R.I.	25 2	29 1	60 8	63 7	4 11	3 9	-	2	-	1	3	-
Conn.	6	9	128	63	12	20	-	1	-	-	1	-
MID. ATLANTIC Upstate N.Y.	84 37	125 46	382 122	631 108	424 66	567 62	-	2 1	-	5 4	7 5	13 2
N.Y. City	24	35	162	246	254	263	-	-	-	-	-	10
N.J. Pa.	21 2	25 19	70 28	106 171	64 40	95 147	-	- 1	-	1	1 1	- 1
E.N. CENTRAL	87	101	476	794	367	352	-	-	-	10	10	6
Ohio Ind.	43 22	32 11	112 43	136 25	59 18	60 26	-	-	-	3 4	3 4	2
III.	10	38	136	342	51	46	-	-	-	3	3	3
Mich. Wis.	6 6	7 13	157 28	245 46	239	204 16	-	-	-	-	-	1
W.N. CENTRAL	31	31	194	432	104	143	-	4	-	-	4	1
Minn. Iowa	15	16	14 18	113 44	13 13	16 15	-	2	-	-	2	1
Mo.	10	8	54	193	55	76	-	2	-	-	2	-
N. Dak. S. Dak.	4	2	2 1	2	- 1	2	-	-	-	-	-	-
Nebr. Kans.	1 1	3 2	24 81	19 61	11 11	23 11	-	-	-	-	-	-
S. ATLANTIC	221	157	944	600	637	545	_	3		1	4	_
Del.	-	-	-	10	-	7	-	-	-	-	-	-
Md. D.C.	51 -	42	128 21	74 11	69 8	68 16	-	2	-	1 -	3	-
Va. W. Va.	16 5	28 4	66 6	71 43	72 14	74 6	-	-	-	-	-	-
N.C.	29 5	15	63	89	105	123	-	-	-	-	-	-
S.C. Ga.	58	5 45	27 369	23 80	11 165	5 90	-	- 1	-	-	- 1	-
Fla.	57	18	264	199	193	156	-	-	-	-	-	-
E.S. CENTRAL Ky.	53 2	30 11	158 26	236 28	196 17	226 46	-	2 2	-	-	2 2	-
Tenn.	27 23	12 5	72	87	99	99	-	-	-	-	-	-
Ala. Miss.	23	2	52 8	30 91	42 38	25 56	-	-	-	-	-	-
W.S. CENTRAL	24	38	591	1,116	333	504	-	1	-	-	1	-
Ark. La.	- 3	- 12	31 46	86 44	48 26	54 74	-	-	-	-	-	-
Okla. Tex.	21	24 2	81 433	139 847	47 212	65 311	-	- 1	-	-	- 1	-
MOUNTAIN	- 95	73	433	420	272	240	_	-		- 1	1	- 12
Mont.	-	-	5	2	2	3	-	-	-	-	-	-
ldaho Wyo.	1 4	3 1	36 16	16 3	6 16	4	Ū	-	Ū	1	1	-
Colo. N. Mex.	23 12	14 16	35 13	94 39	55 73	44 74	-	-	-	-	-	2
Ariz.	42	31	219	202	84	80	-	-	-	-	-	-
Utah Nev.	6 7	6 2	37 39	30 34	14 21	14 21	-	-	-	-	-	3 7
PACIFIC	52	70	1,009	1,734	550	651	-	24	-	7	31	13
Wash. Oreg.	1 15	3 21	50 39	144 116	57 28	40 49	-	13 1	-	2	15 1	3
Calif.	32 3	26	908	1,453	459	551	-	8	-	4	12	7
Alaska Hawaii	3 1	2 18	12	10 11	4 2	4 7	-	2	-	- 1	- 3	1 2
Guam	-	1	-	1	-	9	U	-	U	-	-	-
P.R. V.I.	1	3	52	159	93	130	U U	-	U U	-	-	2
Amer. Samoa	U	U U	U	U U	U 19	U U	U	U	Ŭ	U	U	U U
C.N.M.I.	-	U	-	U	19	U	-	-	-	-	-	U

TABLE III. Provisional cases of selected notifiable diseases preventable
by vaccination, United States, weeks ending June 23, 2001,
and June 24, 2000 (25th Week)

N: Not notifiable. U: Unavailable. - : No reported cases. *For imported measles, cases include only those resulting from importation from other countries. † Of 148 cases among children aged <5 years, serotype was reported for 66, and of those, 10 were type b.

		jococcal ease		Mumps			Pertussis		Rubella			
Reporting Area	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000	
UNITED STATES	1,250	1,260	-	82	190	42	2,047	2,668	-	11	72	
NEW ENGLAND Maine	76 1	72 5	-	-	2	6	228	732 14	-	-	10	
N.H.	9	7	-	-	-	2	21	62	-	-	1	
Vt. Mass.	4 43	2 43	-	-	-	- 1	22 169	148 471	-	-	- 8	
R.I. Conn.	2 17	5 10	-	-	1 1	1 2	2 14	8 29	-	-	- 1	
MID. ATLANTIC	101	136	-	5	12	-	140	237	-	4	7	
Upstate N.Y. N.Y. City	41 23	36 28	-	1 4	5 4	-	100 23	124 39	-	1 2	1 6	
N.J. Pa.	29 8	24 48	-	-	- 3	-	8 9	- 74	-	1 -	-	
E.N. CENTRAL	159	219	-	9	17	1	240	299	-	3	-	
Ohio Ind.	57 26	45 24	-	1 1	7	1 -	146 20	161 27	-	- 1	-	
III. Mich.	20 29	58 71	-	6 1	5 4	-	26 24	23 31	-	2	-	
Wis.	27	21	-	-	1	-	24	57	-	-	-	
W.N. CENTRAL Minn.	90 13	84 7	-	6 2	10	7	109 31	124 59	-	2	1	
lowa Mo.	20 31	19 42	-	-	5 2	4 3	15 45	17 24	-	1	-	
N. Dak. S. Dak.	5	2	-	-	-	-	- 3	1	-	-	-	
Nebr. Kans.	8 9	5 4 5	-	- 1 3	1 2	-	2 13	3 17	-	- - 1	1	
S. ATLANTIC	9 231	5 175	-	3 17	28	- 3	107	17	-	1	31	
Del. Md.	29	17	-	- 4	-	- 1	15	4 47	-	-	-	
D.C. Va.	- 25	- 29	-	- 2	- 5	-	1 12	1 20	-	-	-	
W. Va.	6	8	-	-	- 3	-	1	-	-	-	-	
N.C. S.C.	50 22	29 15	-	1 1	9	-	39 19	49 17	-	-	23 6	
Ga. Fla.	32 67	32 45	-	7 2	2 3	2	6 14	20 29	-	- 1	2	
E.S. CENTRAL	83	89 17	-	2	4	2	43 11	51	-	-	4	
Ky. Tenn.	14 32	17 38	-	1 -	2	- 1	18	28 11	-	-	1	
Ala. Miss.	29 8	25 9	-	- 1	2	1 -	11 3	9 3	-	-	3	
W.S. CENTRAL Ark.	160 10	142 7	-	6 1	21 1	1	108 4	123 12	-	-	6 1	
La.	52	34	-	2	4	-	2	7	-	-	1	
Okla. Tex.	18 80	21 80	-	- 3	16	- 1	1 101	9 95	-	-	4	
MOUNTAIN Mont.	70 2	59 1	-	7	13 1	6 2	865 8	367 8	-	-	1	
Idaho	6	6	-	-	-	1	162	41	-	-	-	
Wyo. Colo.	5 25	19	U -	1 1	1	U	151	1 207	U -	-	- 1	
N. Mex. Ariz.	10 11	6 18	-	2 1	1 3	2	57 455	60 34	-	-	-	
Utah Nev.	7 4	6 3	-	1 1	4 3	1	22 9	10 6	-	-	-	
PACIFIC	280	284	-	30	83	16	207	548	-	1	12 7	
Wash. Oreg.	41 20	29 32	Ň	1 N	2 N	10 6	66 19	185 46	-	-	-	
Calif. Alaska	215 2	211 4	-	23 1	64 7	-	117 1	284 11	-	-	5	
Hawaii	2 2	8	-	5	10	-	4	22	-	1	-	
Guam P.R.	- 3	- 6	U U	-	7 -	U U	2	3 3	U U	-	1	
V.I. Amer. Samoa	Ū	Ū	U U	Ū	- U	U U	Ū	Ū	U U	Ū	Ū	
C.N.M.I.	-	Ŭ	-	-	Ŭ	-	-	Ŭ	-	-	Ŭ	

TABLE III. (Cont'd) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending June 23, 2001, and June 24, 2000 (25th Week)

N: Not notifiable. U: Unavailable.

- : No reported cases.

All Causes, By				Age (Ye	ears)		P&I⁺		All Causes, By Age (Years)						P&I⁺
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total
NEW ENGLAND Boston, Mass. Bridgeport, Conn Cambridge, Mass. Fall River, Mass. Hartford, Conn. Lowell, Mass. Lynn, Mass. New Bedford, Ma New Haven, Conn Providence, R.I. Somerville, Mass. Springfield, Mass. Waterbury, Conn. Worcester, Mass. MID. ATLANTIC Albany, N.Y. Allentown, Pa. Buffalo, N.Y. Camden, N.J. Elizabeth, N.J. Erie, Pa.§	611 138 47 356 56 56 56 53 355 5 355 4 4 2,279 42 42 42 42 42 34 51 35 35	427 866 32 4 30 33 19 6 200 38 50 340 160 50 30 30 30 30 30 30 30 30 30 30 30 30 30	4 13 4 6 3 5 14 1 4 6 10 446 8 - 19 9 3 4	39 13 4 - 5 - 1 2 4 4 - 3 1 2 138 1 - 3 3 - 3 2	17 3 1 - 2 - 3 3 - 3 - 3 - 1 40 2 - 1 2 - 1	15 5 2 - 2 - 2 - - 5 - 1 - - 5 - 1 - - 35 1 - 1 4 - 1 4 - 1	57 91 431 32 711 439 1126 - 71 -	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla Miami, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, I Tampa, Fla. Washington, D.U Wilmington, De E.S. CENTRAL Birmingham, Al Chattanooga, Te Knoxville, Tenn. Lexington, Ky. Memphis, Tenn Mobile, Ala. Montgomery, A Nashville, Tenn.		873 84 103 68 105 95 46 39 36 46 48 117 115 565 149 40 777 26 50 33 86	275 38 13 33 11 14 5 9 29 51 - 149 25 13 15 31 31 25 25	117 17 17 17 8 95 6 3 4 3 15 20 - 5 8 3 7 2 19 5 2 12	43 76 5 72 5 - 1 22 6 - 17 5 - 12 4 1 - 4 1 -	35 3 4 1 3 2 4 - 3 3 5 7 - 22 5 2 1 1 4 - 2 7	71 4 21 9 6 10 2 3 2 3 10 1 - 63 18 4 2 5 11 3 11 9
Jersey City, N.J. New York City, N.N Paterson, N.J. Philadelphia, Pa. Pittsburgh, Pa.§ Reading, Pa. Rochester, N.Y. Schenectady, N.Y. Scranton, Pa.§ Syracuse, N.Y. Trenton, N.J. Utica, N.Y. Yonkers, N.Y.	U 20 423 34 36 126	33 782 U 11 305 24 32 93 29 19 102 15 20 U	U 5 80 3 20 6 4 20 6 5	2 78 U 4 23 1 - 8 - 2 4 6 1 U	- 19 U - 7 1 - 5 - 1 1 - U	1 11 0 - 8 - 1 - - 4 3 - U	40 4 23 2 1 6 1 2 16 1 2 U	W.S. CENTRAL Austin, Tex. Baton Rouge, La Corpus Christi, Dallas, Tex. El Paso, Tex. Ft. Worth, Tex. Houston, Tex. Little Rock, Ark. New Orleans, La San Antonio, Te Shreveport, La. Tulsa, Okla.	Tex. 43 196 80 99 346 81 . 78	953 43 65 32 117 49 70 177 55 52 143 54 96	321 13 9 44 20 15 79 16 15 46 15 33	149 6 1 23 7 47 7 11 20 6 4	60 - 1 3 3 1 34 - 8 2 1	38 2 - 4 - 6 9 2 - 10 2 3	87 533 88 6 17 1 6 14 6 10
E.N. CENTRAL Akron, Ohio Canton, Ohio Chicago, III. Cincinnati, Ohio Celveland, Ohio Columbus, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind. Grand Rapids, Mid Indianapolis, Ind. Lansing, Mich. Milwaukee, Wis. Peoria, III. Rockford, III. South Bend, Ind. Toledo, Ohio Youngstown, Ohi W.N. CENTRAL Des Moines, Iowa Duluth, Minn. Kansas City, Kans Kansas City, Kans Kansas City, Kans St. St. Paul, Minn. Wichita, Kans.	164 57 140 48 50 47 92 0 84 835 63 39 37 37 102 41	$\begin{array}{c} 1,207\\ 40\\ 30\\ 0\\ 6\\ 932\\ 1423\\ 115\\ 8\\ 510\\ 48\\ 119\\ 47\\ 92\\ 832\\ 32\\ 6\\ 6\\ 92\\ 5\\ 5\\ 5\\ 5\\ 5\\ 6\\ 6\\ 7\\ 0\\ 30\\ 8\\ 15\\ 6\\ 4\\ 5\\ 5\\ 6\\ 6\\ 5\\ 5\\ 6\\ 6\\ 5\\ 6\\ 6\\ 6\\ 7\\ 30\\ 8\\ 6\\ 5\\ 5\\ 6\\ 6\\ 5\\ 6\\ 6\\ 6\\ 7\\ 30\\ 8\\ 6\\ 5\\ 6\\ 6\\ 5\\ 6\\ 6\\ 6\\ 7\\ 30\\ 8\\ 6\\ 6\\ 5\\ 6\\ 6\\ 6\\ 7\\ 6\\ 6\\ 6\\ 7\\ 6\\ 6\\ 6\\ 7\\ 6\\ 6\\ 6\\ 7\\ 7\\ 8\\ 6\\ 6\\ 6\\ 7\\ 7\\ 8\\ 6\\ 6\\ 7\\ 7\\ 8\\ 6\\ 6\\ 7\\ 7\\ 8\\ 6\\ 6\\ 7\\ 7\\ 8\\ 6\\ 6\\ 7\\ 7\\ 8\\ 6\\ 6\\ 7\\ 7\\ 8\\ 6\\ 7\\ 7\\ 8\\ 6\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 7\\ 8\\ 7\\ 8\\ 7\\ 7\\ 8\\ 8\\ 8\\ 7\\ 8\\ 7\\ 8\\ 8\\ 8\\ 7\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\ 8\\$	31 44 28 51 7 12 4 9 22 5 32 6 12 10 15 12 14 8 2 9 17 6 23 12 29 16 23 12 29 16	99 4 - U 5 101 11 4 8 1 3 - 5 12 4 11 2 3 5 8 3 63 1 8 3 20 9 12 5 5	47 1 - U 2 4 10 1 5 - 2 1 2 7 1 4 1 1 - 2 3 27 - 1 5 2 9 3 4 - 3	32 1 - U 1 7 1 1 4 - 1 2 2 4 - 1 1 2 2 2 1 1 1 - 2 - 1 - 4 2 1 - 1 - 4 2 1	105 1 4 U 8 6 110 12 2 3 · 7 9 4 10 2 3 2 8 3 5 5 7 · 1 7 2 13 9 3 3 5	MOUNTAIN Albuquerque, N Boise, Idaho Colo. Springs, C Denver, Colo. Las Vegas, Nev. Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, U Tucson, Ariz. PACIFIC Berkeley, Calif. Fresno, Calif. Glendale, Calif. Honolulu, Hawa Long Beach, Cal Los Angeles, Ca Pasadena, Calif. Portland, Oreg. Sacramento, Ca San Jose, Calif. Sant Francisco, C San Jose, Calif. Santa Cruz, Cali Seattle, Wash. Tacoma, Wash. TOTAL	47 colo. 67 117 158 29 158 26 tah 96 115 1,704 16 59 21 177 if. 432 28 177 if. 432 29 . 173 talif. U 173 talif. U 173 talif. U	$\begin{array}{c} 657\\ 97\\ 37\\ 44\\ 73\\ 111\\ 26\\ 102\\ 18\\ 6\\ 6\\ 7\\ 82\\ 1,235\\ 10\\ 47\\ 16\\ 65\\ 56\\ 42\\ 303\\ 20\\ 128\\ 148\\ 135\\ 0\\ 125\\ 199\\ 65\\ 50\\ 71\\ 8,128\\ \end{array}$	$\begin{array}{c} 184\\ 33\\ 7\\ 11\\ 26\\ 35\\ 2\\ 30\\ 4\\ 120\\ 310\\ 4\\ 5\\ 14\\ 12\\ 5\\ 33\\ 447\\ U\\ 3\\ 5\\ 24\\ 5\\ 11\\ 2,275\\ \end{array}$	78 15 1 9 12 9 1 12 10 8 9 4 1 5 - 5 5 6 2 8 8 9 U 1 1 7 1 5 8 35 8 35	27 3 4 1 9 1 2 3 6 - 3 6 - 0 4 - 6 - 3 14	16 1 2 2 2 6 1 1 2 2 4 1 2 2 4 1 2 2 4 1 1 3 3 4 7 1 3 4 7 1 2 2 2 4 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2	62 6 6 1 16 5 4 16 - 5 3 15 8 - 1 1 8 8 4 1 3 13 5 22 U 10 4 5 8 9 765

TABLE IV. Deaths in 122 U.S. cities,* week ending June 23, 2001 (25th Week)

U: Unavailable. -: No reported cases. *Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. *Pneumonia and influenza.

[®]Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. [®]Total includes unknown ages.

Contributors to the Production of the MMWR (Weekly)

Weekly Notifiable Disease Morbidity Data and 122 Cities Mortality Data

Samuel L. Groseclose, D.V.M., M.P.H.

State Support Team Robert Fagan Jose Aponte Gerald Jones David Nitschke Scott Noldy Jim Vaughan Carol A. Worsham

CDC Operations Team Carol M. Knowles Deborah A. Adams Willie J. Anderson Patsy A. Hall Suzette A. Park Felicia J. Perry Pearl Sharp

Informatics

T. Demetri Vacalis, Ph.D.

Michele D. Renshaw

Erica R. Shaver

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/Publications/mmwr. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control and Prevention Jeffrey P. Koplan, M.D., M.P.H.	Director, Epidemiology Program Office Stephen B. Thacker, M.D., M.Sc.	Writers-Editors, <i>MMWR</i> (Weekly) Jill Crane David C. Johnson						
Deputy Director for Science and Public Health, Centers for Disease Control and Prevention David W. Fleming, M.D.	Editor, <i>MMWR</i> Series John W. Ward, M.D. Acting Managing Editor, <i>MMWR</i> (Weekly) Teresa F. Rutledge	Desktop Publishing Lynda G. Cupell Morie M. Higgins						
☆U.S. Government Printing Office: 2001-633-173/48241 Region IV								